Management of Bronchitis and COPD Exacerbations

Pharmacologic Interventions

• The American Thoracic Society recommends starting with ipratropium bromide 36 μg (2 inhalations) four times daily as first-line therapy, combined with a short-acting β-agonist for acute symptom relief in patients with bronchitis and COPD exacerbation 1, 2
• The European Respiratory Society suggests that ipratropium bromide has Grade A evidence for improving cough in stable COPD patients with chronic bronchitis and provides bronchodilation within 30-90 minutes, lasting 4-6 hours 3, 4, 2
• Short-acting β-agonists control bronchospasm and relieve dyspnea, with onset within 15-30 minutes and duration of 4-5 hours, as recommended by the European Respiratory Society 4, 2
• The American College of Chest Physicians recommends that during acute exacerbations, both anticholinergic and β-agonist bronchodilators should be administered together; if no prompt response occurs, maximize the dose of the second agent 1, 2
• The European Respiratory Society recommends prescribing antibiotics empirically for 7-10 days if the patient has increased dyspnea, increased sputum volume, or increased sputum purulence (at least 2 of 3 Anthonisen criteria) 5, 4, 6
• First-line antibiotic options include amoxicillin 500 mg three times daily for 7-10 days, doxycycline 100 mg twice daily for 7-10 days, and azithromycin 500 mg once daily for 3 days, as recommended by the European Respiratory Society 5, 4, 6
• The American Journal of Respiratory and Critical Care Medicine suggests that systemic corticosteroids reduce exacerbation duration and improve lung function during acute flares 7, 2
• The American Thoracic Society recommends administering a short course (10-15 days) of systemic corticosteroids for acute exacerbations: oral prednisone 30-40 mg daily for outpatients or IV methylprednisolone for hospitalized patients 7, 1, 2

Non-pharmacologic Interventions

• The American Journal of Respiratory and Critical Care Medicine recommends smoking cessation as the most effective intervention, with 90% of patients reporting resolution of chronic cough after quitting 3, 2
• The American Thoracic Society suggests that pulmonary rehabilitation should be included for patients with high symptom burden and risk of exacerbations (GOLD groups B, C, and D) 7
• The American Journal of Respiratory and Critical Care Medicine recommends influenza and pneumococcal vaccinations for all COPD patients 7

Monitoring and Follow-up

• The European Respiratory Society recommends reassessing 2-3 days after starting antibiotics to evaluate treatment response 6
• The European Respiratory Society suggests reevaluating if fever persists beyond 3 days, suggesting bacterial superinfection or pneumonia rather than simple viral bronchitis 6
• The European Respiratory Society recommends considering alternative diagnoses if cough persists beyond 3 weeks, including asthma, pertussis, or gastroesophageal reflux 6